Note murp-20261011-001 · Murphy · measurement
Week of 2026-10-05
to 2026-10-11.
Published 2026-10-13T12:45:02Z. Fingerprint (SHA-256): ba253df9ec45950b48d541c15c8079d9ab0e37a308643bf6402b8531d4e3ac88. Shares are percentages of all stories in the fixed collection that week.
Header
| denominator stories | 63393 |
|---|---|
| desk | murphy |
| field | Health technology, as a public argument |
| method | backtest: over 47 reconstructed weeks the forecast was closer than the four-week mean in 0.49 of weeks; mean error 0.132 against 0.130 points; skill guard pass · filing rule: claims-policy-v1: forecast = median4 · reading: Claims test whether the record is auditable. The backtest does not show skill over the four-week mean. |
| period end | 2026-10-11 |
| period start | 2026-10-05 |
| quota used | 239 |
| reconstructed history | 2025-10-06 to 2026-09-28 (52 weeks, retrieved after the fact; used for baselines and dynamics, never for claims) |
| versions | articles: articles-v1 · collection: collection-v1 · collector: collect-v1 · dynamics: dynamics-v1 · response: response-v1 · topics: topics-v1 |
What gained share
| topic | share | last | trailing mean | change | numerator | denominator | thin |
|---|---|---|---|---|---|---|---|
| agency politics | 0.62 | 0.46 | 0.53 | 0.16 | 393 | 63393 | no |
| drug pricing access | 0.24 | 0.13 | 0.11 | 0.10 | 150 | 63393 | no |
| insurance coverage | 0.21 | 0.12 | 0.12 | 0.09 | 132 | 63393 | no |
| telehealth digital | 0.37 | 0.31 | 0.33 | 0.06 | 235 | 63393 | no |
| privacy data | 0.18 | 0.12 | 0.12 | 0.06 | 113 | 63393 | no |
| research funding | 0.16 | 0.13 | 0.14 | 0.03 | 102 | 63393 | no |
| device approval | 0.05 | 0.02 | 0.03 | 0.03 | 30 | 63393 | no |
| clinical trial results | 0.27 | 0.25 | 0.31 | 0.02 | 169 | 63393 | no |
| vaccines | 0.56 | 0.55 | 0.73 | 0.01 | 354 | 63393 | no |
| glp1 obesity drugs | 0.18 | 0.19 | 0.23 | -0.01 | 115 | 63393 | no |
| drug approval | 0.19 | 0.23 | 0.25 | -0.04 | 121 | 63393 | no |
| ai in care | 0.41 | 0.54 | 0.47 | -0.14 | 257 | 63393 | no |
A larger fraction of coverage is not the same as a rewritten article.
What is only being repeated
| clusters | mean outlets per cluster | n | rate | repeated | topic |
|---|---|---|---|---|---|
| 8 | 5.88 | 93 | 0.49 | 46 | privacy data |
| 5 | 6.40 | 73 | 0.44 | 32 | insurance coverage |
| 5 | 6 | 75 | 0.40 | 30 | research funding |
| 26 | 6.50 | 391 | 0.39 | 154 | agency politics |
| 7 | 5.86 | 125 | 0.32 | 40 | drug pricing access |
| 8 | 5.88 | 106 | 0.31 | 33 | telehealth digital |
| 1 | 7 | 25 | 0.28 | 7 | device approval |
| 3 | 8 | 108 | 0.22 | 24 | drug approval |
| 8 | 4.88 | 184 | 0.21 | 38 | vaccines |
| 6 | 5 | 151 | 0.20 | 30 | clinical trial results |
| 6 | 6.17 | 214 | 0.18 | 38 | ai in care |
| 2 | 3 | 74 | 0.08 | 6 | glp1 obesity drugs |
What attention did
| series | week total | last week | trailing median | ratio | direction |
|---|---|---|---|---|---|
| wp.Artificial intelligence in healthcare.daily | 1047 | 1245 | 964 | 1.09 | down |
| wp.Centers for Disease Control and Prevention.daily | 4303 | 3885 | 4145.50 | 1.04 | up |
| wp.Centers for Medicare & Medicaid Services.daily | 836 | 910 | 902 | 0.93 | down |
| wp.Clinical trial.daily | 821 | 905 | 1009.50 | 0.81 | down |
| wp.Continuous glucose monitor.daily | 816 | 666 | 517.50 | 1.58 | up |
| wp.Electronic health record.daily | 1014 | 1027 | 997.50 | 1.02 | down |
| wp.Food and Drug Administration.daily | 5013 | 5095 | 5001 | 1.00 | down |
| wp.GLP-1 receptor agonist.daily | 3948 | 4488 | 4232.50 | 0.93 | down |
| wp.Health Insurance Portability and Accountability Act.daily | 2427 | 2571 | 3077.50 | 0.79 | down |
| wp.Medicare Advantage.daily | 1130 | 817 | 631.50 | 1.79 | up |
| wp.National Institutes of Health.daily | 2206 | 2102 | 2183 | 1.01 | up |
| wp.Prior authorization.daily | 149 | 149 | 172.50 | 0.86 | flat |
| wp.Robotic surgery.daily | 367 | 449 | 437 | 0.84 | down |
| wp.Semaglutide.daily | 8385 | 9525 | 9497.50 | 0.88 | down |
| wp.Telehealth.daily | 554 | 769 | 743.50 | 0.75 | down |
| wp.Vaccine.daily | 6497 | 6245 | 2779 | 2.34 | up |
Pageviews and search say people looked. They do not say people agreed.
Chatter
No chatter series.
Cross-check
| series | week total | last week | trailing median | ratio | direction | same direction as top mover | source updated |
|---|---|---|---|---|---|---|---|
| fr.cms.all.daily | 5 | 8 | 3.50 | 1.43 | down | no | — |
| fr.fda.all.daily | 24 | 11 | 14 | 1.71 | up | yes | — |
| fr.fda.device.daily | 11 | 8 | 6 | 1.83 | up | yes | — |
| fr.hhs.all.daily | 63 | 48 | 45.50 | 1.38 | up | yes | — |
| gi.bills.health.weekly | 8 | — | — | — | — | — | — |
| gi.crec.health.weekly | 2 | — | — | — | — | — | — |
| fda.510k.weekly | 0 | — | — | — | — | — | None (provisional) |
| fda.device recall.weekly | 51 | — | — | — | — | — | 2026-10-12 |
| fda.drugsfda submissions.weekly | 39 | — | — | — | — | — | 2026-10-09 (provisional) |
| fda.pma.weekly | 0 | — | — | — | — | — | None (provisional) |
A clearance, a recall or a registration is a count of a process. It is not evidence that a technology works or is safe.
openFDA counts: "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated." (openFDA)
What has no second series
Nothing to show for this period.
Claims
No claims filed. The claim log opens for this desk at Release 4.
Differs
| last week | drug_pricing_access, clinical_trial_results, insurance_coverage |
|---|---|
| this week | agency_politics, drug_pricing_access, insurance_coverage |
Dynamics
| agency politics | D1 onset: 2025-12-29 · D2 height ratio: 1.60 · D2 peak: 2026-01-05 · D3 half life weeks: — · D3 note: decay not observed yet · D3 points: 40 · D3 r2: — · D4 span: 2 · D5 persistence: 4: 0.57 · 12: 0.47 · D6 reignitions: 2 · n weeks: 53 |
|---|---|
| ai in care | D1 onset: — · D6 reignitions: 0 · n weeks: 53 · note: no burst |
| clinical trial results | D1 onset: — · D6 reignitions: 0 · n weeks: 53 · note: no burst |
| device approval | D1 onset: — · D6 reignitions: 0 · n weeks: 53 · note: no burst |
| drug approval | D1 onset: — · D6 reignitions: 0 · n weeks: 53 · note: no burst |
| drug pricing access | D1 onset: — · D6 reignitions: 0 · n weeks: 53 · note: no burst |
| glp1 obesity drugs | D1 onset: — · D6 reignitions: 0 · n weeks: 53 · note: no burst |
| insurance coverage | D1 onset: — · D6 reignitions: 0 · n weeks: 53 · note: no burst |
| privacy data | D1 onset: — · D6 reignitions: 0 · n weeks: 53 · note: no burst |
| research funding | D1 onset: 2026-07-20 · D2 height ratio: 2.43 · D2 peak: 2026-07-27 · D3 half life weeks: 0.40 · D3 note: — · D3 points: 11 · D3 r2: 0.60 · D4 span: 2 · D5 persistence: 4: 0.40 · 12: — · D6 reignitions: 1 · n weeks: 53 |
| telehealth digital | D1 onset: — · D6 reignitions: 0 · n weeks: 53 · note: no burst |
| vaccines | D1 onset: 2025-12-01 · D2 height ratio: 2.47 · D2 peak: 2025-12-01 · D3 half life weeks: — · D3 note: decay not observed yet · D3 points: 45 · D3 r2: — · D4 span: 2 · D5 persistence: 4: 0.54 · 12: 0.57 · D6 reignitions: 2 · n weeks: 53 |
Notes, not calls.